Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial

BACKGROUND: We aimed to evaluate icatibant, a competitive antagonist of the bradykinin B2 receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) pneumonia admitted in the early hypoxemic stage. METHODS: The randomized, open-label clinical trial of icatibant for COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Malchair, Pierre, Giol, Jordi, García, Vanesa, Rodríguez, Orlando, Ruibal, José Carlos, Zarauza, Alvaro, Llopis, Ferrán, Matellán, Leire, Bernal, Tania, Solís, Beatriz, Otero, Aurema, Carnaval, Thiago, Jofre, Hector, Jacob, Javier, Solanich, Xavier, Antolí, Arnau, Rocamora, Gemma, Videla, Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209439/
https://www.ncbi.nlm.nih.gov/pubmed/36610464
http://dx.doi.org/10.1093/cid/ciac984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209439/
https://www.ncbi.nlm.nih.gov/pubmed/36610464
http://dx.doi.org/10.1093/cid/ciac984

Ejemplares similares